HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology

$HTGM HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders. The Agreement is a next step in the parties’ relationship following the successful adaptation of Firalis’ BIOPRED* research‑use assay to HTG EdgeSeq technology.https://finance.yahoo.com/news/htg-molecul...

Read more

Recommended & Related Posts

Edited Transcript of HTGM earnings conference call or presentation 8-Nov-18 9:30pm GMT

$HTGM Q3 2018 HTG Molecular Diagnostics Inc Earnings Callhttps://finance.yahoo.com/news/edited-tran...

Read more
HTG Molecular Presenting at Upcoming Healthcare Conferences

$HTGM TUCSON, Ariz., Nov. 12, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications,.https://finance.yahoo.com/news/htg-molecul...

Read more
Edited Transcript of HTGM earnings conference call or presentation 8-Nov-18 9:30pm GMT

$HTGM Q3 2018 HTG Molecular Diagnostics Inc Earnings Callhttps://finance.yahoo.com/news/edited-tran...

Read more
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates

$HTGM HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 10.53% and -8.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?https://finance.yahoo.com/news/htg-molecul...

Read more
HTG Molecular Diagnostics Reports Third Quarter 2018 Results

$HTGM Revenue increased 26% and 101% for the three and nine months ended September 30, 2018 compared to the respective prior year periods Call scheduled for today, November 8, at.https://finance.yahoo.com/news/htg-molecul...

Read more

There are more for you ...

View more and participate in our discussion now. It's FREE.

Creating an account means you’re okay with InvestingNote's Terms and Conditions